Business
Helix BioPharma Corp. Announces Filing of Interim Financial Statements as of and for the Three and Six Month Periods Ended January 31, 2025
(TheNewswire) March 18, 2025 – TheNewswire - Toronto, Ontario – Helix Bio...
About this update from Helix Biopharma Corp.
[{"type":"text","content":"Helix BioPharma Corp. Announces Filing of Interim Financial Statements as of and for the Three and Six Month Periods Ended January 31, 2025\n\n\n (TheNewswire)\n \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n March 18, 2025 – TheNewswire -\n \n\n Toronto, Ontario – Helix BioPharma Corp. (TSX:\n \n\n “HBP”\n \n\n , OTC PINK:\n \n\n “HBPCD”\n \n\n , FRANKFURT:\n \n\n “HBP0”\n \n\n ) (\n \n\n “Helix”\n \n\n or the\n \n\n “Company”\n \n\n ), a clinical-stage oncology company shaping a near future\nwhere today’s hard-to-treat cancers are vincible, announces the\nfiling of the Company’s unaudited interim financial statements as of\nand for the three and six month periods ended January 31, 2025 (the\n \n\n “Financial\nStatements”\n \n\n ), the management’s discussion\nand analysis (\n \n\n “MD&A”\n \n\n ), and the certifications of the\nChief Executive Officer and Chief Financial Officer (respectively,\n \n\n “CEO”\n \n\n and\n \n\n “CFO”\n \n\n ) relating to the Financial\nStatements (collectively, the\n \n\n “Interim Filings”\n \n\n ). The Interim Filings\nare available on the Company’s profile at\n \n\n\n\n www.sedarplus.ca\n \n\n\n\n .\n \n\n\n\n About Helix BioPharma\n \n\n\n\n Helix BioPharma Corp. is an oncology company shaping a\nnear future where today’s hard-to-treat cancers are made vincible by\nnovel therapies that rise to the challenge. The Company innovates from\nstrength to tackle cancer’s biggest, most urgent challenges with a\ndiverse pipeline of drug candidates with great potential and a head\nstart, honed into first- and best-in-class oncology medicines. Its\npipeline is spearheaded by a clinical-stage proprietary technology\nplatform of bio-conjugates that score with precision against prevalent\nCEACAM6-expressing solid tumors. Its lead candidate, Tumour Defence\nBreaker\n \n\n TM\n \n\n L-DOS47, is a clinical-stage antibody-enzyme conjugate (AEC)\nthat neutralizes the microenvironment of common, hard-to-treat solid\ntumors, taking the brakes off anti-cancer immunity and delivering a\ngame-changing assist to today’s front-running anti-cancer therapies.\nL-DOS47 has completed Phase Ib studies in non-small cell lung cancer\n(NSC...